ARQTArcutis Biotherapeutics, Inc.
$26.56+53% 1Y
$26.56
$16.7352 weeks$31.20
Latest close: back above its 200-day averageOct 9, 2026what changed →
ARQT in its own filings
Nothing in ARQT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
150
Events found in the filings · across 848 filings · the record starts in 2019
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Oct 7, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 27, 2026
- SEC comment-letter activity21 occurrences
- 2025-12-02
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.Earnings release · Form 8-K
- Jul 16, 2026On July 15, 2026, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board.Director or officer change · Form 8-K
- Jun 9, 2026As part of a regular review of the corporate governance practices of the Company and in an effort to continue to attract and retain qualified members of the Company’s Board of Directors (the “Board”), which includes compensating eligible non-employee directors appropriately for their services, the Compensation …Shareholder vote results · Form 8-K
- May 6, 2026Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update.Material event (exhibits only) · press release
- Feb 25, 2026Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Dec 8, 2025On December 3, 2025, Mr. Bhaskar Chaudhuri retired from his positions as a member of the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) and chair of the Compensation Committee of the Board.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…